[ Price : $8.95]
Federal Register Notice: FDAs Oncologic Drugs Advisory Committee will meet 12/2 to discuss Bristol-Myers Squibbs BLA for advanced ...[ Price : $8.95]
Federal Register Notice: FDA plans a public workshop 12/9-10 on product development programs for patients with severe bleeding due...[ Price : $8.95]
FDA announces a two-day public workshop on products to intervene in patients with severe bleeding.[ Price : $8.95]
FDA grants Hyperion Therapeutics a fast track designation for HPN-100 (glycerol phenylbutyrate) and its use as an adjunctive thera...[ Price : $8.95]
ReGen says FDA politics and false allegations are behind the decision to rescind 510(k) clearance for its Menaflex knee implant.[ Price : $8.95]
An FDA advisory committee 10/18 votes 15 to 1 that erythropoiesis stimulating agents can continue to be used in kidney disease pat...[ Price : $8.95]
Former Office of Generic Drugs director Gary Buehler is becoming Tevas vice president of regulatory strategic operations.[ Price : $8.95]
FDA rejects a Sanofi-Aventis request on bioequivalence testing for generic Ambien CR products.